From NASH to MASH: Current Market Dynamics in Hepatology (Podcast)

From NASH to MASH: Current Market Dynamics in Hepatology

Guests: Pete Bak and Christian Thienel
Length: 28 minutes
Airdate: September16, 2024

After a summer away from podcasting, Back Bay Life Science Advisors’ Dr. Pete Bak and Christian Thienel are back on the mic to discuss current market dynamics in liver disease with a focus on one of the most closely watched space in hepatology, MASH.

The big news includes a rebrand from NASH (non-alcohol related steatohepatitis) to MASH (metabolic dysfunction-associated steatohepatitis), the FDA approval of Madrigal Pharmaceutical’s Rezdiffra and real-time court rulings in Europe that may affect the rate of play for Ocaliva, a drug used to treat adults with primary biliary cholangitis here in the US. As Christian mentions in this episode, “The path to success is not always a straight line.”

Other topics in this podcast include:

  • Hepatology market dynamics over the past five years, including activity from Gilead, Novo Nordisk, Intercept and CymaBay

  • How treatment for primary biliary cholangitis, an autoimmune condition, went from a one to a three-product market

  • Payer monographs and what’s required for hepatology drugs

  • The EMA recommendation earlier this month to revoke Ocaliva’s marketing authorization

  • Which companies are active in the rare liver disease space and how they differentiate themselves

PodcastBack Bay Life Science AdvisorsMASH, NASH, Hepatoglogy, Biotech development